Claudin18.2 CAR-T cell therapy (Ucello Therapeutics)

N/A

Report date: 2025/12/08 20:00:58

Base Information

Drug NameClaudin18.2 CAR-T cell therapy (Ucello Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionClaudin 18 protein modulatorsT lymphocyte replacements
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesUcello Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUcello Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A